Loading...
Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC
INTRODUCTION: Abiraterone acetate plus prednisone (AA+P) has shown to significantly improve survival. COSMiC, a Canadian Observational Study in Metastatic Cancer of the Prostate, set out to prospectively amass real-world data on metastatic castration-resistant prostate cancer (mCRPC) patients manage...
Na minha lista:
| Udgivet i: | Can Urol Assoc J |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Canadian Medical Association
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7704085/ https://ncbi.nlm.nih.gov/pubmed/32569568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.6388 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|